Mónica Muñoz

734 total citations
45 papers, 485 citations indexed

About

Mónica Muñoz is a scholar working on Toxicology, Public Health, Environmental and Occupational Health and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Mónica Muñoz has authored 45 papers receiving a total of 485 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Toxicology, 10 papers in Public Health, Environmental and Occupational Health and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Mónica Muñoz's work include Pharmacovigilance and Adverse Drug Reactions (19 papers), Academic integrity and plagiarism (8 papers) and Pharmaceutical studies and practices (6 papers). Mónica Muñoz is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (19 papers), Academic integrity and plagiarism (8 papers) and Pharmaceutical studies and practices (6 papers). Mónica Muñoz collaborates with scholars based in United States, Colombia and Spain. Mónica Muñoz's co-authors include Cindy Kortepeter, Gerald J. Dal Pan, Eileen Wu, R. M. Devine, Mark Avigan, Heidi Nelson, Donald E. Engen, Gregory G. Tsiotos, Marta Romeu and Allen Brinker and has published in prestigious journals such as SHILAP Revista de lepidopterología, PEDIATRICS and American Journal of Epidemiology.

In The Last Decade

Mónica Muñoz

41 papers receiving 476 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mónica Muñoz United States 14 138 95 52 50 48 45 485
Hélène Théophile France 15 228 1.7× 71 0.7× 28 0.5× 42 0.8× 36 0.8× 28 602
C. Kreft-Jaïs France 14 249 1.8× 138 1.5× 67 1.3× 36 0.7× 44 0.9× 38 774
Alexandra Păcurariu Netherlands 12 184 1.3× 39 0.4× 30 0.6× 35 0.7× 50 1.0× 24 524
Salvatore Crisafulli Italy 15 153 1.1× 74 0.8× 100 1.9× 183 3.7× 41 0.9× 38 872
Gianmario Candore Netherlands 9 326 2.4× 27 0.3× 32 0.6× 40 0.8× 45 0.9× 18 515
Ola Caster Sweden 14 451 3.3× 42 0.4× 62 1.2× 62 1.2× 69 1.4× 26 832
Kristina Juhlin Sweden 12 391 2.8× 30 0.3× 39 0.8× 43 0.9× 21 0.4× 17 554
Nancy Yuen United States 7 287 2.1× 32 0.3× 44 0.8× 30 0.6× 13 0.3× 9 534
Suzie Seabroke United Kingdom 8 216 1.6× 35 0.4× 38 0.7× 47 0.9× 7 0.1× 12 418
Ana Alvarez-Requejo Spain 8 247 1.8× 66 0.7× 17 0.3× 25 0.5× 110 2.3× 13 576

Countries citing papers authored by Mónica Muñoz

Since Specialization
Citations

This map shows the geographic impact of Mónica Muñoz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mónica Muñoz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mónica Muñoz more than expected).

Fields of papers citing papers by Mónica Muñoz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mónica Muñoz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mónica Muñoz. The network helps show where Mónica Muñoz may publish in the future.

Co-authorship network of co-authors of Mónica Muñoz

This figure shows the co-authorship network connecting the top 25 collaborators of Mónica Muñoz. A scholar is included among the top collaborators of Mónica Muñoz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mónica Muñoz. Mónica Muñoz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Rongmei, et al.. (2025). An Evaluation of Duplicate Adverse Event Reports Characteristics in the Food and Drug Administration Adverse Event Reporting System. Drug Safety. 48(10). 1119–1126. 1 indexed citations
2.
3.
Summan, Mukesh, et al.. (2024). Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients. Pediatric Nephrology. 39(8). 2429–2433. 1 indexed citations
4.
5.
Wu, Eileen, et al.. (2023). Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010–2020: A Cross-Sectional Study. Therapeutic Innovation & Regulatory Science. 57(5). 1062–1073. 6 indexed citations
6.
Kortepeter, Cindy, et al.. (2022). Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions. Dermatologic Clinics. 40(3). 265–277. 2 indexed citations
7.
Jenkins, Marjorie, Mónica Muñoz, Daniel Bąk, et al.. (2021). Food and Drug Administration Beyond the 2001 Government Accountability Office Report: Promoting Drug Safety for Women. Journal of Women s Health. 30(7). 927–934. 5 indexed citations
8.
Pham, Phuong, Eileen Wu, Rongmei Zhang, et al.. (2021). Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports. Pharmaceutical Medicine. 35(5). 307–316. 8 indexed citations
9.
Kreimeyer, Kory, et al.. (2021). Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System. Computers in Biology and Medicine. 135. 104517–104517. 32 indexed citations
10.
Jones, S. Christopher, et al.. (2020). An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System. Drug Safety. 43(5). 457–465. 14 indexed citations
11.
Muñoz, Mónica, Gerald J. Dal Pan, Yu‐Jung Jenny Wei, et al.. (2020). Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. Drug Safety. 43(4). 329–338. 21 indexed citations
12.
Muñoz, Mónica & Gerald J. Dal Pan. (2019). The Impact of Litigation-Associated Reports on Signal Identification in the US FDA’s Adverse Event Reporting System. Drug Safety. 42(10). 1199–1201. 5 indexed citations
13.
Harinstein, Lisa, et al.. (2018). Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance. Drug Safety. 42(5). 649–655. 14 indexed citations
14.
Muñoz, Mónica, et al.. (2017). Anti-natural octyl disaccharide-leprosy IDRI diagnostic (NDO-LID) antibodies as indicators of leprosy reactions and neuritis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 111(3). 125–131. 9 indexed citations
15.
Muñoz, Mónica, Wei Liu, Joseph A. Delaney, et al.. (2013). Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care. JAIDS Journal of Acquired Immune Deficiency Syndromes. 64(3). 254–260. 16 indexed citations
16.
Muñoz, Mónica, María Rosa Nogués, Marta Romeu, et al.. (2011). Toxicology evaluation of a procyanidin-rich extract from grape skins and seeds. Food and Chemical Toxicology. 49(6). 1450–1454. 49 indexed citations
17.
Arriola, Edurne, Matilde Navarro, David Parés, et al.. (2006). Imaging Techniques Contribute to Increased Surgical Rescue of Relapse in the Follow-Up of Colorectal Cancer. Diseases of the Colon & Rectum. 49(4). 478–484. 30 indexed citations
18.
Muñoz, Mónica, et al.. (1998). Management of acquired rectourinary fistulas. Diseases of the Colon & Rectum. 41(10). 1230–1238. 46 indexed citations
19.
Toro, Jorge R., et al.. (1991). Adherencia al tratamiento de la tuberculosis del adulto en Santiago, Chile. 111(5). 423–431. 10 indexed citations
20.
Clanet, Michel, M. Abbal, Mónica Muñoz, et al.. (1986). [Analysis of the cerebrospinal fluid by isoelectrofocusing on agarose in multiple sclerosis].. PubMed. 142(8-9). 677–82. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hélène Théophile Breakdown of academic impact, for papers by C. Kreft-Jaïs Breakdown of academic impact, for papers by Alexandra Păcurariu Breakdown of academic impact, for papers by Salvatore Crisafulli Breakdown of academic impact, for papers by Gianmario Candore Breakdown of academic impact, for papers by Ola Caster Breakdown of academic impact, for papers by Kristina Juhlin Breakdown of academic impact, for papers by Nancy Yuen Breakdown of academic impact, for papers by Suzie Seabroke Breakdown of academic impact, for papers by Ana Alvarez-Requejo
Rankless by CCL
2026